Bio Ascend Logo

Accreditation

Target Audience

The target audience for this activity is Oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of patients with lung cancer. 

Learning Objectives

  • Optimize the selection of therapy for patients with lung cancer based on the results of molecular testing, disease-specific characteristics, and patient-related factors 
  • Integrate emerging clinical trial safety and efficacy results regarding the treatment of patients with lung cancer in order to have informed clinical decision making and personalize the care for each individual patient 
  • Evaluate approaches to mitigate treatment-related adverse events that may occur during the treatment of patients with lung cancer 
  • Develop strategies to enhance participation in clinical trials for both healthcare professionals and patients with lung cancer

Accreditation

Resim1

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend.  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Education

Partners designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Disclosures 

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships. 

Faculty disclosure information coming soon. 

Instructions for Credit 

To receive CE credit, learners must follow these steps: 

  1. Link for activity evaluation coming soon 
  2. Complete the activity evaluation 
  3. Upon completion of all evaluation questions, your credit will be made available for download immediately. 

 

ALCS 2025 COI Faculty

Fatemeh Ardeshir, MD, MSc

Has no relevant financial relationships

Hossein Borghaei, DO, MS

Paul Bunn, MD

Consultant, Advisor, Speaker: AstraZeneca, Aveo, BMS, Daiichi Sankyo, Dizal, Genentech, Merck, Verastem

Jennifer Carlisle, MD

Consultant, Advisor, Speaker: Amgen, AstraZeneca, Catalyst, Lilly

Jamie Chaft, MD

Consultant, Advisor, Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Guardant, Exact Sciences, FMI, Merck, Natera

Researcher: AstraZeneca, Boehringer Ingelheim, Genentech, Lilly, Merck, BioNtech, Taiho

Shirish Gadgeel, MD

Consultant, Advisor, Speaker: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Genentech, Gilead, Johnson + Johnson, Pfizer, Takeda

John Heymach, MD, PhD

Has no relevant financial relationships

Onkar Khullar, MD, MSc

Has no relevant financial relationships

Kelsey Pan, MD, MPH

Consultant, Advisor, Speaker: Janssen Pharmaceuticals

Gregory Riely, MD, PhD

Researcher: Amgen, Lilly, Mirati/BMS, Takeda

Joshua Sabari, MD

Consultant, Advisor, Speaker: AstraZeneca, AbbVie, Boehringer Ingelheim, Genentech, J&J Janssen, Jazz, Loxo, Lilly, BMS/Mirati, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda

Conor Steuer, MD

Consultant, Advisor, Speaker: BMS, Boehringer Ingelheim, Daiichi Sankyo, Fennec, Merck, Novocure, Regeneron

Sibo Tian, MD

Consultant, Advisor, Speaker: Castle, Merck

Researcher: Varian

Heather Wakelee, MD

Consultant, Advisor, Speaker: AstraZeneca, Beigene(BeOne), BMS, GSK, Genentech/Roche, IOBioTech, Mirati, OncoC4

Researcher: AstraZeneca, Bayer, BMS, Genentech/Roche, Helsinn, Merck, SeaGen, Xcovery, Gilead via IIT (Georgetown)

We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.

OK